Kim, Jae Hoon http://orcid.org/0000-0001-5643-0913
Song, Ji Hye http://orcid.org/0000-0002-3952-5096
Kim, MinYoung http://orcid.org/0009-0003-8812-412X
Hong, Jang Hee http://orcid.org/0000-0002-0623-5455
Sunwoo, Jung http://orcid.org/0000-0001-8801-0323
Jung, Jin-Gyu http://orcid.org/0000-0002-2591-4867
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants
https://doi.org/10.1007/s12325-024-02869-y
Documents that mention this clinical trial
Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants
https://doi.org/10.1007/s12325-024-02869-y
Article History
Received: 9 December 2023
Accepted: 4 April 2024
First Online: 21 May 2024
Declarations
:
: MinYoung Kim is an employee of Chong Kun Dang Pharm. Corp., Yongin, Republic of Korea. The other authors (Jae Hoon Kim, Ji Hye Song, Jang Hee Hong, Jung Sunwoo and Jin-Gyu Jung) declare no conflict of interest in this study.
: These studies were conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practice and the International Conference on Harmonization and the study protocol was approved by the MFDS and the Chungnam National University Hospital IRB (study 1: IRB No. CNUH 2020-06-031, study 2: IRB No. CNUH 2020-09-117). Both studies 1 and 2 were registered at ClinicalTrials.gov (study 1: NCT04478097; study 2: NCT04627207). All study participants gave informed consent. The informed consent form was reviewed and approved by the MFDS and the IRB.